Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S6. Change in expression of indicated signatures between baseline and post-treatment in PET nonresponders (A–D). Change in PD-L1 TAP scores between baseline and post-treatment in (E) PET responders and (F) PET nonresponders.